Analysis of the Performance of the CONTOUR® TS Blood Glucose Monitoring System: When Regulatory Performance Criteria are Met,Should We Have Confidence to Use a Medical Device with All Patients?

Abstract

The article entitled, Performance of the CONTOUR® TS Blood Glucose Monitoring System, by Frank and colleagues in this issue of Journal of Diabetes Science and Technology, demonstrates that the CONTOUR® TS glucose meter exceeds current regulatory expectations for glucose meter performance. However, the appropriateness of current regulatory expectations, such as International Organization for Standardization (ISO) 15197:2003, is being reevaluated because of increasing concern regarding the reliability of glucose meters in ambulatory and hospitalized environments. Between 2004 and 2008, 12,673 serious adverse events with glucose meters that met the ISO 15197 expectations were reported in the Food and Drug Administration-Manufacturer and User Facility Device Experience surveillance database. Should different glucose meter performance criteria be applied to ambulatory versus critical care patients?

Keywords

assisted-monitoring blood glucose devices ISO 15197:2003 accuracy performance expectations MAUDE surveillance system database self-monitoring blood glucose devices

References

Klonoff

. The Food and Drug Administration is now preparing to establish tighter performance requirements for blood glucose monitors. J Diabetes Sci Technol. 2010; 4 (3): 499–504.

Frank

Wallace

Pardo

Parkes

. Performance of the CONTOUR® TS blood glucose monitoring system. J Diabetes Sci Technol. 2011; 5 (1): 198–205.

Sacks

Bernhardt

Dunka

Jr Goldstein

Hortin

Mueller

; CLS/NNCLS. Point of care blood glucose testing in acute and chronic facilities; approved guideline—second edition. CLSI/NCCLS document C30-A2. Wayne, PA: NCCLS. 2002; 22 (11).

International Organization for Standardization. ISO 15197. In vitro diagnostic test systems. Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Geneva, Switzerland: International Organization for Standardization. 2003.

U. S. Food and Drug Administration. MAUDE — Manufacturer and user facility device experience. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM. Accessed November 12, 2010.

U. S. Food and Drug Administration. Analysis of glucose meter medical device reporting (MDR)/MAUDE database. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/medsun/news/newsletter.cfm?news=21. Accessed November 12, 2010.

Lyon

Gray

Baskin

DuBois

Lyon

. A mathematical model to assess the influence of hematocrit on point of care glucose meter performance. Clin Biochem. 2010; 43 (10–11): 905–9.

Lyon

DuBois

Fick

Lyon

. Estimates of total analytical error in consumer and hospital glucose meters contributed by hematocrit, maltose and ascorbate. J Diabetes Sci Technol. 2010; 4 (6): 1479–94.